Vocal Biomarker Market
Vocal Biomarker Market By Technique (Frequency, Amplitude, Error Rate, Vocal Rise or Fall Time, Phonation Time, Voice Tremor, Pitch), By Indication (Psychiatric Disorders, Respiratory Disorders, Cardiovascular Disorders, TBI, Neurological Disorders), By End User & Region - Global Market Insights 2023 to 2033
Analysis of Vocal Biomarker market covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Vocal Biomarkers Market Outlook (2023 to 2033)
The global vocal biomarkers market size stands at US$ 2.3 billion in 2023 and is forecasted to surpass a valuation of US$ 9 billion by 2033-end. Over the next ten years, global demand for vocal biomarkers is estimated to surge at a CAGR of 14.7%.
Clinical psychologists have been using vocal cues and voice samples to analyse personality traits, and this is now being taken one step further with the development of vocal biomarkers, which combine the functionality of biological markers on a vocal basis. These new biomarkers have immense potential in detecting various diseases and health conditions by sampling an individual’s voice.
Rising investments in healthcare research & development, growing focus on advanced diagnostic procedures, increasing popularity of non-invasive medical procedures, supportive government initiatives, advancements in biomarker technology, and rapid adoption of advanced technologies such as artificial intelligence and machine learning in medical applications are prime factors that are forecasted to boost vocal biomarker demand in the future. Increasing demand for remote patient monitoring solutions is projected to create a highly lucrative business scope for vocal biomarker providers across the forecast period.
On the contrary, errors in the interpretation of vocal characteristics and inaccuracies in word boundaries are anticipated to be key restraints impeding overall vocal biomarkers market development in the long run. However, high investments in R&D are projected to help reduce errors and improve the diagnostic capabilities of vocal biomarkers over the next ten years.
Increasing focus on mental health and the rising willingness of people to spend on mental well-being products is also expected to induce huge changes in the current and forecasted pricing trends associated with vocal biomarkers.
More new developments and trends altering market developments have been discussed in detail in this latest vocal biomarkers market research report by Fact.MR, a market research and competitive intelligence provider.
Vocal Biomarkers Market Size (2023)
US$ 2.3 Billion
Projected Market Value (2033F)
US$ 9.1 Billion
Global Market Growth Rate (2023 to 2033)
Leading Regional Market
Key Companies Profiled
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Factors Could Audibly Promulgate Vocal Biomarker Demand?
“Growing Prevalence of Cardiovascular & Neurological Disorders”
The world has witnessed a substantial increase in the incidence of cardiovascular disorders in the past few years and this has led to high demand for new and advanced diagnostic procedures to fast-track diagnosis and treatment. Increasing stress levels and the growing prevalence of anxiety have resulted in rising cases of neurological and psychological disorders, which has led to high demand for novel diagnostic procedures that help in the diagnosis of complicated health conditions.
Growing incidence of dementia, cardiovascular diseases, Parkinson’s disease, and Alzheimer’s disease is anticipated to bolster demand for vocal biomarkers in the long run. Increasing awareness about the efficacy of vocal biomarkers to identify and diagnose symptoms of the aforementioned diseases is slated to create new opportunities for established as well as upcoming vocal biomarker companies.
“Increasing Investments in Research & Development of Advanced Diagnostic Procedures”
Vocal biomarkers are a result of recent advancements and the proliferation of advanced technology in the medical industry. The technology is still in its nascent stages and has immense potential to develop in the future. Vocal biomarker vendors are focusing on realizing this potential by increasing investments in their R&D programs that will help them fast-track the development of novel vocal biomarkers. The companies are also expected to opt for collaborations, partnerships, and mergers to gain a competitive advantage over other market players over the coming years.
How Can Start-ups Penetrate the Competitive Vocal Biomarkers Marketplace?
“New Vocal Biomarker Companies making Inroads through Development of Innovative Solutions”
New vocal biomarker companies are projected to focus on innovation to create solutions that cater to the increasing global demand. Growing focus on mental health and behavioral health is projected to open up new avenues of opportunities for new entrants in the global industry landscape.
- In August 2021, Ellipsis Health, a leading vocal biomarker company in collaboration with Cigna International developed and announced the launch of the Cigna StressWaves Test. It is an online tool that analyzes voice patterns and acoustics to evaluate stress levels in an individual. The tool uses Ellipsis’s advanced AI technology that enables stress detection through voice.
- OpaMind, an Irish mental health start-up founded in 2020 that has been recognized as a top innovator in mental health by the World Economic Forum uses vocal biomarkers to analyze users’ voices. The technology used by OpaMind was developed with help from researchers at Dublin City University (DCU).
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Should Vocal Biomarker Companies Invest in Japan & Korea?
“Large Geriatric Population and Increasing Investments in Healthcare Infrastructure Development”
Japan is home to one of the world’s most prominent sects of the aging population which is projected to increase at a high pace over the coming years as well. The increasing senescent population has resulted in growing cases of dementia, Alzheimer’s disease, and Parkinson’s disease, which is projected to boost demand for vocal biomarkers as they have been proven to diagnose the aforementioned health conditions to some extent.
- In April 2022, the National Cerebral and Cardiovascular Center (NCVC) of Japan and Canary Speech, a United States-based leading vocal biomarker company announced a collaboration to enable the early detection of dementia by using AI vocal biomarkers in the Japanese language. The initiative will be a part of Japan’s effort to take care of its rapidly increasing senescent population.
Korea is also projected to offer a highly opportunistic setting for vocal biomarker companies across the forecast period owing to increasing focus on healthcare and rising investments in healthcare infrastructure development. Collaborations and partnerships to advance the study of vocal biomarkers are expected to be rife in the country over the next ten years.
- In November 2022, KT Corporation, a leading South Korean telecommunications company announced that it was investing US$ 2 million in Sonde Health, a health technology firm. The companies also collaborated to upgrade KT’s AI-powered voice business solutions and Sonde’s technology was intended to be used in KT’s telemedicine platform in Vietnam.
How Will Vocal Biomarker Demand Fare in European Countries?
“Growing Awareness Regarding Use of Voice Analysis Technology in Healthcare”
People in the European region have become increasingly aware of the use of voice analysis technology for various health conditions and this is a prominent trend that is projected to boost demand for vocal biomarkers market in countries such as Germany, Italy, and the United Kingdom across the forecast period.
Growing awareness of neurological disorders, an increasing aging population, rising healthcare expenditure, and high investments in medical research are other factors that are slated to promulgate vocal biomarkers market demand in European countries through 2033.
What Makes the United States a Highly Remunerative Market?
“Rapid Adoption of Advanced Technologies and Investments in Healthcare R&D”
The United States is a country known for its advanced healthcare infrastructure and is also famous for being quick in the adoption of advanced healthcare technologies and trends. Expenditure on healthcare and investments in research and development has been continually increasing in the country which has created a highly opportune setting for the advancement of novel medical technologies such as vocal biomarkers. Supportive government initiatives and a developed healthcare infrastructure further bolster market development potential in the country going forward.
The high prevalence of cardiovascular diseases, growing cases of Alzheimer’s and Parkinson’s diseases, the presence of key vocal biomarker companies, and favorable reimbursement infrastructure are other factors that could potentially boost vocal biomarker demand through 2033. The growing aging population is also expected to be a prominent influential aspect affecting market potential over the next ten years.
Which Disorder Accounts for a Leading Market Share?
“Cardiovascular Disorders Projected to Spearhead Vocal Biomarker Demand”
Based on indication, the vocal biomarkers market is segmented into psychiatric disorders, respiratory disorders, cardiovascular disorders, traumatic brain injury (TBI), neurological disorders, and other disorders.
Sedentary lifestyles and poor eating habits have resulted in a high prevalence of cardiovascular disorders, and the number of people affected by the aforementioned disorder is projected to increase significantly over the coming years. Vocal biomarkers have been shown to successfully detect cardiovascular health complications in many studies and this is projected to boost the use of vocal biomarkers in the diagnosis and treatment of the condition in the future.
Neurological disorders also account for a significant market share as vocal characteristics are largely influenced by involuntary muscle movement stemming from the brain and vocal biomarkers can reflect these changes to help in diagnosis and treatment.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Top vocal biomarker providers are focusing on developing and launching new solutions that help them maximize the application of vocal biomarkers for different use cases.
- In October 2021, Sonde Health revealed a mental health monitoring technology that uses a voice sample to evaluate the mental well-being of an individual. The Sonde Mental Fitness technology was available as an application programming interface (API) for wellness service providers, health systems, and employers.
Key Segments of Vocal Biomarker Industry Research
By Technique :
- Error Rate
- Vocal Rise or Fall Time
- Phonation Time
- Voice Tremor
By Indication :
- Psychiatric Disorders
- Respiratory Disorders
- Cardiovascular Disorders
- Traumatic Brain Injury (TBI)
- Neurological Disorders
- Other Disorders
By End User :
- Hospitals & Clinics
- Contract Research Organizations (CROs)
- Academic & Research Centers
- Other End Users
By Region :
- North America
- Latin America
- FAQs -
The global vocal biomarkers market accounts for a value of US$ 2.3 billion in 2023.
By 2033-end, the vocal biomarker market is estimated to reach US$ 9.1 billion.
Demand for vocal biomarkers is anticipated to exhibit expansion at a prolific 14.7% CAGR over the next ten years.
North America is projected to account for a significant share of the global market.
Cogito Corporation, Kintsugi, Sharecare Inc., Microtest Health, and Sonde Health are some key suppliers of vocal biomarkers.